Cargando…

Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy

Background: To evaluate the short-term outcomes of switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy (PCV). Methods: This retrospective study included 18 eyes diagnosed with aflibercept-resistant PCV. All patients were treated with two to four consecutive ranibizuma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeon, Young-Joon, Kim, Jae-Hui, Kim, Jong-Woo, Kim, Chul-Gu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704610/ https://www.ncbi.nlm.nih.gov/pubmed/34945034 http://dx.doi.org/10.3390/jcm10245739

Ejemplares similares

Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Jin, Ki Won, et al.
Publicado: (2021)

Short-term Effectiveness of Intravitreal Bevacizumab vs. Ranibizumab Injections for Patients with Polypoidal Choroidal Vasculopathy
por: Cho, Han Joo, et al.
Publicado: (2012)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)

Therapeutic effects of ranibizumab in patients with polypoidal choroidal vasculopathy
por: Gu, Xiaoya, et al.
Publicado: (2019)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
por: Wong, James G., et al.
Publicado: (2017)

Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
por: Lee, Sang Eun, et al.
Publicado: (2019)

Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept
por: Xue, Yin, et al.
Publicado: (2022)

Regression in polypoidal choroidal vasculopathy treated with ziv-aflibercept monotherapy – short term study
por: Mishra, Sai B., et al.
Publicado: (2022)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014)

Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy
por: Ito, Arisa, et al.
Publicado: (2020)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Long-Term Outcomes of Switching from Fixed-Dose to As-Needed Regimen for Treating Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy
por: Kim, Jae Hui, et al.
Publicado: (2020)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab
por: Sonoda, Shozo, et al.
Publicado: (2013)

One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
por: Kwon, Ji Min, et al.
Publicado: (2021)

Optical Coherence Tomography-based Diagnosis of Polypoidal Choroidal Vasculopathy in Korean Patients
por: Chang, Young Suk, et al.
Publicado: (2016)

Polypoidal Choroidal Vasculopathy with Feeder Vessels: Characteristics, Fellow Eye Findings, and Long-term Treatment Outcomes
por: Hwang, Hyun Ji, et al.
Publicado: (2017)

Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy
por: Ma, I-Hsin, et al.
Publicado: (2021)

Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study
por: Lee, Joo Eun, et al.
Publicado: (2016)

Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy
por: Ho, Mary, et al.
Publicado: (2016)

Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy
por: Arakawa, Akira, et al.
Publicado: (2017)

Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
por: Miyakubo, Tomoko, et al.
Publicado: (2023)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma, Keiko, et al.
Publicado: (2018)

One-Year Outcome of Aflibercept and Photodynamic Therapy in a Caucasian Patient with Polypoidal Choroidal Vasculopathy Refractory to Ranibizumab and Photodynamic Therapy
por: Medina-Baena, Marta, et al.
Publicado: (2018)

Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort
por: Liu, Siyin, et al.
Publicado: (2022)

Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
por: Bansal, Aditya, et al.
Publicado: (2017)

Choroidal structure as a biomarker for visual acuity in intravitreal aflibercept therapy for polypoidal choroidal vasculopathy
por: Asano, Shotaro, et al.
Publicado: (2018)

Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy
por: Hikichi, Taiichi, et al.
Publicado: (2013)

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence
por: Soman, Manoj, et al.
Publicado: (2022)

Long-term Clinical Course after Vitrectomy for Breakthrough Vitreous Hemorrhage Secondary to Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Kim, Jae Hui, et al.
Publicado: (2020)

Intravitreal Anti-vascular Endothelial Growth Factor for Treating Polypoidal Choroidal Vasculopathy with Grape-like Polyp Clusters
por: Chang, Young Suk, et al.
Publicado: (2016)

Comment on: Aflibercept for recurrent or recalcitrant polypoidal choroidal vasculopathy in Indian eyes: Early experience
por: Kathiriya, Vidhi, et al.
Publicado: (2018)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2020)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Polypoidal choroidal vasculopathy in a case of retinitis pigmentosa, successfully treated with intravitreal aflibercept
por: Takahashi, Nana, et al.
Publicado: (2021)

One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
por: Choo, Hun Gu, et al.
Publicado: (2021)

Reduction in choroidal thickness of macular area in polypoidal choroidal vasculopathy patients after intravitreal ranibizumab therapy
por: Nishide, Tadayuki, et al.
Publicado: (2013)

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
por: Nemoto, Rei, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mn02ipodbaasvtjgbvaq0jvtth